We serve Chemical Name:3-(diethylamino)propanoic acid CAS:6972-41-4 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
Chemical Name:3-(diethylamino)propanoic acid
CAS.NO:6972-41-4
Synonyms:RARECHEM AL BO 0310;3-diethylaminopropionic acid;3-Diaethylamino-propionsaeure;N,N-diethylamino-3-propionic acid
Molecular Formula:C7H15NO2
Molecular Weight:145.19900
HS Code:
Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:40.54000
Exact Mass:145.11000
LogP:0.80290
Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:
Packing Group:
Contact us for information like RARECHEM AL BO 0310 chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N,N-diethylamino-3-propionic acid physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,3-Diaethylamino-propionsaeure Use and application,RARECHEM AL BO 0310 technical grade,usp/ep/jp grade.
Related News: Novartis and GSK carried out a swap of its vaccine and cancer drugs back in 2015. GSK paid $5.25 billion to Novartis for its vaccine business, and Novartis sent $16 billion for GSK’s oncology programs. Tafinlar and Mekinist had already been granted FDA approval at the time of that deal, and as a part of that deal, Novartis agreed to divest its own BRAF and MEK inhibitors to avoid creating a monopoly. dimethyl (3aS,5S,6aS)-5-amino-3a,5,6,6a-tetrahydro-4H-cyclopenta[d]isoxazole-3,5-dicarboxylate manufacturers A thorough safety and risk analysis procedure should be administered at an appropriate time with documentation that adheres to the rules and regulations set forth by the regulatory authorities. Naphthalene-1,8-disulfide-S-oxide suppliers Professor Xiangdong Cheng, secretary of party committee of Cancer Hospital of the University of Chinese Academy of Sciences (Zhejiang Cancer Hospital) and Chief of Zhejiang Province Upper Gastrointestinal Tumor Diagnosis and Treatment Technology Research Center, stated: The progress of immunotherapy in certain types of colorectal cancer and gastric cancer has not been satisfactory compared with the progress of anti-PD-1 monoclonal antibodies in melanoma, lung cancer and esophageal cancer, and this needs further exploration.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Hexanoyl chloride, 6-[4-[[4-(decyloxy)phenyl]azo]phenoxy]-, (E)- vendor & factory.
TIGIT is highly expressed in gastric cancer. And pre-clinical experiments have proved that synergistically targeting PD-1 and TIGIT could significantly repress gastric tumor growth. We look forward to the clinical results of IBI321, particularly in GI tumors.
Dr. Hui Zhou, Senior Vice President of Clinical Development of Innovent, stated: “By specifically targeting both PD-1 and TIGIT, this type of bispecific antibody is designed to provide synergistic effects by blocking both the PD-1/PD-L1 and TIGIT/CD155 pathways – with the goal of improving the anti-cancer efficacy.
Currently, there is no bispecific antibody that has same target as IBI321 in clinical-stage development worldwide. Preclinical studies of IBI321 have demonstrated that the combination of these two monoclonal antibodies further enhanced the immune activation with improved convenience of administration.
Therefore, the development of an anti-PD-1/TIGIT bispecific antibody has the potential to provide patients with more effective and convenient treatment. We look forward to hope that IBI321 will benefit more patients. Hexanoyl chloride, 6-[4-[[4-(decyloxy)phenyl]azo]phenoxy]-, (E)- vendor & factory.
